Toulouse: Flash Therapeutics sets up at the Oncopole, on the Pierre Fabre site, to grow even further
To meet the requirements of drug agencies, Flash Therapeutics has moved to the Pierre Fabre Innovation Center. Biotechnology remains independent.
For its third move since its creation in 2005, Flash Therapeutics (formerly Vectalys) has changed universes and practices. No more trucks rented from a furniture dealer and cramped spaces. Head to the Health Campus of the Future at the Oncopole in the huge Pierre Fabre innovation site. On the first floor of module 5, the bright rooms of the open space; in the basement, the “GMP” area of the bioproduction platform which marks the entry of Toulouse society into a new era.
“To meet the requirements of drug agencies, we needed a GMP (Good Manufacturing Practices) labeled area. The premises must be designed and secured for the production of medicines and this is what we found here at Pierre Fabre thanks to the help of Toulouse Métropole which hosted us at Canal Biotech ”, explains Pascale Bouillé, president and founder of Flash Therapeutics.
“We are very happy to contribute in this way to the dynamism of the Oncopole and to its attractiveness. Our two companies are completely independent, but it is obvious that informal contacts will have to be created between scientists, and this can only be beneficial for all ”, commented Marc Alias, Director of Communication and Engagement of the group. Pierre Fabre, adding that the site still has free office and laboratory space to accommodate other biotechs.
“The buttons for opening doors or elevators are separate but nothing prevents exchanges: they bring us the industrial world, we bring our dynamism”, adds Pascale Bouillé.
Of 800 m2, Flash Therapeutics’ production and research area will reach 2,500 m2 by the end of 2022 to produce its first batches of drugs with RNA technology made in Toulouse.